Commonwealth Equity Services’s Integra LifeSciences IART Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.42M | Buy |
+150,570
| New | +$1.65M | ﹤0.01% | 2302 |
|
|
2024
Q2 | – | Sell |
-7,930
| Closed | -$281K | – | 4105 |
|
|
2024
Q1 | $281K | Buy |
7,930
+99
| +1% | +$3.96K | ﹤0.01% | 3330 |
|
|
2023
Q4 | $341K | Buy |
7,831
+153
| +2% | +$6.02K | ﹤0.01% | 3062 |
|
|
2023
Q3 | $293K | Buy |
7,678
+3
| +0% | +$126 | ﹤0.01% | 3052 |
|
|
2023
Q2 | $316K | Sell |
7,675
-241
| -3% | -$11.6K | ﹤0.01% | 3010 |
|
|
2023
Q1 | $454 | Buy |
7,916
+263
| +3% | +$14.8K | ﹤0.01% | 2642 |
|
|
2022
Q4 | $429K | Sell |
7,653
-1,275
| -14% | -$64.9K | ﹤0.01% | 2592 |
|
|
2022
Q3 | $378K | Sell |
8,928
-470
| -5% | -$24.1K | ﹤0.01% | 2631 |
|
|
2022
Q2 | $507K | Sell |
9,398
-829
| -8% | -$49.8K | ﹤0.01% | 2388 |
|
|
2022
Q1 | $657K | Sell |
10,227
-163
| -2% | -$10.7K | ﹤0.01% | 2310 |
|
|
2021
Q4 | $696K | Buy |
10,390
+419
| +4% | +$28.3K | ﹤0.01% | 2257 |
|
|
2021
Q3 | $682K | Buy |
9,971
+150
| +2% | +$10.6K | ﹤0.01% | 2235 |
|
|
2021
Q2 | $670K | Buy |
9,821
+2,845
| +41% | +$201K | ﹤0.01% | 2229 |
|
|
2021
Q1 | $481K | Buy |
6,976
+131
| +2% | +$8.88K | ﹤0.01% | 2360 |
|
|
2020
Q4 | $444K | Sell |
6,845
-831
| -11% | -$44.7K | ﹤0.01% | 2231 |
|
|
2020
Q3 | $362K | Buy |
7,676
+845
| +12% | +$40.2K | ﹤0.01% | 2219 |
|
|
2020
Q2 | $320K | Sell |
6,831
-4,061
| -37% | -$200K | ﹤0.01% | 2235 |
|
|
2020
Q1 | $486K | Sell |
10,892
-725
| -6% | -$38K | ﹤0.01% | 1714 |
|
|
2019
Q4 | $677K | Buy |
11,617
+36
| +0.3% | +$2.14K | ﹤0.01% | 1676 |
|
|
2019
Q3 | $695K | Sell |
11,581
-150
| -1% | -$8.94K | ﹤0.01% | 1591 |
|
|
2019
Q2 | $655K | Sell |
11,731
-139
| -1% | -$7.16K | ﹤0.01% | 1612 |
|
|
2019
Q1 | $661K | Sell |
11,870
-133
| -1% | -$6.77K | ﹤0.01% | 1564 |
|
|
2018
Q4 | $541K | Buy |
12,003
+90
| +0.8% | +$4.94K | ﹤0.01% | 1590 |
|
|
2018
Q3 | $784K | Buy |
11,913
+965
| +9% | +$60K | ﹤0.01% | 1467 |
|
|
2018
Q2 | $705K | Buy |
10,948
+489
| +5% | +$30.3K | ﹤0.01% | 1505 |
|
|
2018
Q1 | $578K | Buy |
10,459
+265
| +3% | +$13.9K | ﹤0.01% | 1621 |
|
|
2017
Q4 | $488K | Buy |
10,194
+824
| +9% | +$40.3K | ﹤0.01% | 1718 |
|
|
2017
Q3 | $473K | Buy |
9,370
+545
| +6% | +$28K | ﹤0.01% | 1651 |
|
|
2017
Q2 | $481K | Buy |
8,825
+2,778
| +46% | +$133K | ﹤0.01% | 1596 |
|
|
2017
Q1 | $255K | Buy |
6,047
+887
| +17% | +$37.9K | ﹤0.01% | 1975 |
|
|
2016
Q4 | $221K | Buy |
+5,160
| New | +$210K | ﹤0.01% | 1985 |
|
Other funds holding IART
RCMNY
PCMI
VPM
VCM
Commonwealth Equity Services's IART Position: Q1 2026 in Review
Commonwealth Equity Services opened a new position in Integra LifeSciences (IART) in Q1 2026: 150,570 shares worth $1.42M. The stake represents ﹤0.01% of the portfolio and ranks #2302 among its holdings. This is a return to the name: Commonwealth Equity Services previously reported a position in IART as recently as Q1 2024.
Commonwealth Equity Services first reported a position in IART in Q4 2016 and has held it in 31 quarters since. 201 funds tracked by Wall St. Rank hold IART as of Q1 2026.
- Commonwealth Equity Services held 150,570 shares of Integra LifeSciences worth $1.42M as of Q1 2026.
- Integra LifeSciences was a new Commonwealth Equity Services position in Q1 2026.
- Integra LifeSciences made up ﹤0.01% of Commonwealth Equity Services's portfolio in Q1 2026, its #2302 holding.
- Commonwealth Equity Services first reported a position in Integra LifeSciences in Q4 2016 and has held it in 31 quarters since.
- 201 funds tracked by Wall St. Rank held Integra LifeSciences as of Q1 2026.
Based on Commonwealth Equity Services's 13F filing for Q1 2026, filed 27 Apr 2026.